Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Strides Arcolab is currently trading at Rs. 781.50, up by 6.65 points or 0.86% from its previous closing of Rs. 774.85 on the BSE.
The scrip opened at Rs. 784.70 and has touched a high and low of Rs. 795.30 and Rs. 770.15 respectively. So far 37383 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 795.30 on 10-Aug-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 795.30 and Rs. 721.00 respectively. The current market cap of the company is Rs. 4590.06 crore.
The promoters holding in the company stood at 28.27% while Institutions and Non-Institutions held 54.03% and 17.70% respectively.
Global pharmaceutical company, Strides Arcolab is mulling to part ways with its injectable medicines unit called Agila Specialties, which might be valued at more than Stride's current market value of $800 million, as mentioned in few media reports. Company’s Agila unit manufactures injectable medicines. The unit so far has a decent track record of winning approvals for its new products, it has supply deals with GlaxoSmithKline and Novartis.
Recently, Strides Arcolab’s wholly owned subsidiary Onco Therapies had received final ANDA approval for Oxaliplatin Injection 50mg/10mL and 100mg/20mL. The company had received tentative approval from USFDA in November 2011 based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1531.05 |
| Dr. Reddys Lab | 6428.05 |
| Cipla | 1482.30 |
| Zydus Lifesciences | 1093.45 |
| Lupin | 1637.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
